Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 27 Dec 2021
Reviewer:  Hiroyuki Uetake
Reviewer's report:
Major points
1) Median follow up duration should be indicated. It seems premature to determine PFS as
patients are enrolled until June 2021.
2) The author should indicate the reason for grouping into PD and non-PD. From Fig. 4, response
rate is high, and it seems better to separate responder and non-responder.
3) The total dose and relative dose intensity of oxaliplatin in each group should be indicated.
These should be related to both effectiveness and PNI.
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 27 Dec 2021
Reviewer:  Hiroyuki Uetake
Reviewer's report:
Major points
1) Median follow up duration should be indicated. It seems premature to determine PFS as
patients are enrolled until June 2021.
2) The author should indicate the reason for grouping into PD and non-PD. From Fig. 4, response
rate is high, and it seems better to separate responder and non-responder.
3) The total dose and relative dose intensity of oxaliplatin in each group should be indicated.
These should be related to both effectiveness and PNI.
Please review this paper.
user
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 27 Dec 2021
Reviewer:  Hiroyuki Uetake
Reviewer's report:
Major points
1) Median follow up duration should be indicated. It seems premature to determine PFS as
patients are enrolled until June 2021.
2) The author should indicate the reason for grouping into PD and non-PD. From Fig. 4, response
rate is high, and it seems better to separate responder and non-responder.
3) The total dose and relative dose intensity of oxaliplatin in each group should be indicated.
These should be related to both effectiveness and PNI.
assistant